India And Brazil Sustain Branded Generics Success For Torrent In Q2
All Eyes Are On The German Market, Which Continues To Inhibit Revenues And Strategic Aims
Executive Summary
Torrent continues its overall growth trajectory in Q2 of its 2023 financial year, but a flagging German market slows the company’s expansion strategy. The board insists improved sales are just around the corner.
You may also be interested in...
US Pricing Pressure Spotlights Regulatory Compliance As Key To Indian Companies’ Performance
While generic drug prices continued to erode in the US during the second quarter of FY23, compliance will be key to the performance of Indian firms such as Torrent and Jubilant through the rest of the year. The US FDA has issued multiple observations in 2022, but an import alert for Glenmark’s Baddi unit is the harshest so far.
Torrent To Build ‘Future Brazil’ In Mexico, Open To Acquisitions In India
Torrent is upping its ambitions in Mexico, the second-largest market in Latin America, where it is to set up a manufacturing hub along with other Indian companies. As sales in the US stagnate, it's also on the acquisition path in India. Meanwhile, building market share for its Januvia generic is going to be an uphill task.
Neuraxpharm’s New Belgian Division Advances European Expansion Strategy
Neuraxpharm continues its European expansion with a new Brussels-based Belgian unit to be headed by country manager Pierre-Hervé Brun. The announcement adds to the more than 20 European countries where the company is recognized and established.